355819-02-2 Usage
Uses
Used in Pharmaceutical Research:
6-BOC-3-AMINO-5,6,7,8-TETRAHYDRO-[1,6]NAPHTHYRIDINE is used as a key intermediate in the synthesis of various pharmaceutical compounds for the development of new drugs and therapeutic agents. Its unique structure and the presence of a protected amino group make it a valuable building block in medicinal chemistry.
Used in Organic Chemistry:
In the field of organic chemistry, 6-BOC-3-AMINO-5,6,7,8-TETRAHYDRO-[1,6]NAPHTHYRIDINE is used as a versatile reagent and a starting material for the synthesis of more complex organic molecules. Its tetrahydronaphthyridine core can be further modified and functionalized to create a wide range of chemical entities with diverse properties and applications.
Used in Chemical Synthesis:
6-BOC-3-AMINO-5,6,7,8-TETRAHYDRO-[1,6]NAPHTHYRIDINE serves as a valuable building block in chemical synthesis, allowing chemists to construct novel compounds with specific functionalities and properties. Its protected amino group can be selectively deprotected under mild conditions, enabling the introduction of various functional groups and the formation of diverse molecular architectures.
Used in Drug Development:
In the process of drug development, 6-BOC-3-AMINO-5,6,7,8-TETRAHYDRO-[1,6]NAPHTHYRIDINE is utilized as a potential lead compound or a structural motif in the design of new therapeutic agents. Its unique chemical properties and the ability to incorporate it into various molecular frameworks make it a promising candidate for the treatment of various diseases and medical conditions.
Used in Chemical Industry:
6-BOC-3-AMINO-5,6,7,8-TETRAHYDRO-[1,6]NAPHTHYRIDINE finds applications in the chemical industry as a specialty chemical, where it can be used to produce a variety of products with specific applications. Its unique structure and reactivity make it suitable for the development of new materials, catalysts, and other chemical products that can be used across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 355819-02-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,5,8,1 and 9 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 355819-02:
(8*3)+(7*5)+(6*5)+(5*8)+(4*1)+(3*9)+(2*0)+(1*2)=162
162 % 10 = 2
So 355819-02-2 is a valid CAS Registry Number.
355819-02-2Relevant articles and documents
COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY
-
, (2021/11/26)
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
-
Paragraph 000457, (2019/11/04)
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
RESORCINOL DERIVATIVE AS HSP90 INHIBITOR
-
, (2017/12/27)
The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.
A facile synthesis of the 3-amino-5,6,7,8-tetrahydro[1,6]naphthyridine system and some alkylated and polycyclic homologues
Harling,Harrington,Thompson
, p. 787 - 797 (2007/10/03)
A facile, two step synthesis of the 3-amino-5,6,7,8-tetrahydro[1,6]naphthyridine system 1 and its more substituted homologues 2-5 via the condensation of mono- and bicyclic-4-piperidinones 11a-c, 12-14 with 3,5-dinitro-1-methyl-2-pyridone 6 in the presenc